136 related articles for article (PubMed ID: 34575662)
1. Real-Time Diabetic Retinopathy Severity Score Level versus Ultra-Widefield Leakage Index-Guided Management of Diabetic Retinopathy: Two-Year Outcomes from the Randomized PRIME Trial.
Yu HJ; Ehlers JP; Sevgi DD; O'Connell M; Reese JL; Srivastava SK; Wykoff CC
J Pers Med; 2021 Sep; 11(9):. PubMed ID: 34575662
[TBL] [Abstract][Full Text] [Related]
2. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes.
Yu HJ; Ehlers JP; Sevgi DD; Hach J; O'Connell M; Reese JL; Srivastava SK; Wykoff CC
Am J Ophthalmol; 2021 Jun; 226():126-136. PubMed ID: 33529593
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial.
Kalra G; Wykoff C; Martin A; Srivastava SK; Reese J; Ehlers JP
Ophthalmol Retina; 2024 Feb; 8(2):116-125. PubMed ID: 37696393
[TBL] [Abstract][Full Text] [Related]
4. The 2-Year Leakage Index and Quantitative Microaneurysm Results of the RECOVERY Study: Quantitative Ultra-Widefield Findings in Proliferative Diabetic Retinopathy Treated with Intravitreal Aflibercept.
Babiuch AS; Wykoff CC; Yordi S; Yu H; Srivastava SK; Hu M; Le TK; Lunasco L; Reese J; Nittala MG; Sadda SR; Ehlers JP
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834478
[TBL] [Abstract][Full Text] [Related]
5. Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy.
Wykoff CC; Nittala MG; Villanueva Boone C; Yu HJ; Fan W; Velaga SB; Ehlers JP; Ip MS; Sadda SR;
Ophthalmol Retina; 2022 Jul; 6(7):557-566. PubMed ID: 35257962
[TBL] [Abstract][Full Text] [Related]
6. Proliferative Diabetic Retinopathy Events in Patients With Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials.
Do DV; Gordon C; Suñer IJ; Reed K; Moini H; Gibson A; Du W; Shah CP
J Vitreoretin Dis; 2022; 6(4):295-301. PubMed ID: 37007930
[TBL] [Abstract][Full Text] [Related]
7. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intravitreal injection of conbercept for moderate to severe nonproliferative diabetic retinopathy.
Shen L; Zheng Y; Gao Z; Li Q; Dai M; Yang W; Zhang Q; Li D; Hu Y; Yuan L
Front Med (Lausanne); 2024; 11():1394358. PubMed ID: 38846145
[TBL] [Abstract][Full Text] [Related]
10. Associations and Prognostic Significance of Fluctuations in Diabetic Retinopathy Severity in Eyes Treated for Diabetic Macular Edema.
Cicinelli MV; Gregori G; Rabiolo A; Tombolini B; Barresi C; Pignatelli F; Lattanzio R; Bandello F
Ophthalmologica; 2023; 246(2):131-140. PubMed ID: 36996777
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies.
Mitchell P; McAllister I; Larsen M; Staurenghi G; Korobelnik JF; Boyer DS; Do DV; Brown DM; Katz TA; Berliner A; Vitti R; Zeitz O; Metzig C; Lu C; Holz FG
Ophthalmol Retina; 2018 Oct; 2(10):988-996. PubMed ID: 31047501
[TBL] [Abstract][Full Text] [Related]
13. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
14. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
Ip MS; Zhang J; Ehrlich JS
Ophthalmology; 2017 May; 124(5):596-603. PubMed ID: 28284785
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy.
Wykoff CC; Eichenbaum DA; Roth DB; Hill L; Fung AE; Haskova Z
Ophthalmol Retina; 2018 Oct; 2(10):997-1009. PubMed ID: 31047503
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial.
Wykoff CC; Nittala MG; Zhou B; Fan W; Velaga SB; Lampen SIR; Rusakevich AM; Ehlers JP; Babiuch A; Brown DM; Ip MS; Sadda SR;
Ophthalmol Retina; 2019 Dec; 3(12):1076-1086. PubMed ID: 31542339
[TBL] [Abstract][Full Text] [Related]
18. Update on Management of Non-proliferative Diabetic Retinopathy without Diabetic Macular Edema; Is There a Paradigm Shift?
Arabi A; Tadayoni R; Ahmadieh H; Shahraki T; Nikkhah H
J Ophthalmic Vis Res; 2022; 17(1):108-117. PubMed ID: 35194501
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept Reduces Retinal Hemorrhages and Intravitreal Microvascular Abnormalities But Not Venous Beading: Secondary Analysis of the CLARITY Study.
Pearce E; Chong V; Sivaprasad S
Ophthalmol Retina; 2020 Jul; 4(7):689-694. PubMed ID: 32473901
[TBL] [Abstract][Full Text] [Related]
20. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
